Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom P Freeman

Showing results (41-50 of 196) with videos related to

Pageof 20
Sort By:
BMJ (Clinical Research Ed.)|April 6, 2019
Medicinal use of cannabis based products and cannabinoidsTom P Freeman, Chandni Hindocha, Sebastian F Green, et al.
Social Cognitive and Affective Neuroscience|February 15, 2014
Dopamine, urges to smoke, and the relative salience of drug versus non-drug rewardTom P Freeman, Ravi K Das, Sunjeev K Kamboj, et al.
Addiction (Abingdon, England)|June 1, 2026
Can Thailand replace a commercialised cannabis market for adult use with a medical prescription model?Rasmon Kalayasiri, Woraphat Ratta-Apha, Jack Wilson, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 2, 2010
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]Celia J A Morgan, Gráinne Schafer, Tom P Freeman, et al.
The Lancet Regional Health. Europe|November 22, 2021
Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment ratesJakob Manthey, Tom P Freeman, Carolin Kilian, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 30, 2010
Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabisCelia J A Morgan, Tom P Freeman, Gráinne L Schafer, et al.
Addiction (Abingdon, England)|July 15, 2021
Weeding out the truth: a systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependenceJack Wilson, Katherine Mills, Tom P Freeman, et al.
The Lancet. Psychiatry|July 28, 2022
Association of cannabis potency with mental ill health and addiction: a systematic reviewKat Petrilli, Shelan Ofori, Lindsey Hines, et al.
Elife|November 13, 2019
The effects of psychosocial stress on dopaminergic function and the acute stress responseMichael Ap Bloomfield, Robert A McCutcheon, Matthew Kempton, et al.
The International Journal on Drug Policy|February 12, 2022
Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendeesMeryem Grabski, Jon Waldron, Tom P Freeman, et al.
Pageof 20

Showing results (41-50 of 196) with videos related to

Sort By:
Pageof 20
BMJ (Clinical Research Ed.)|April 6, 2019
Medicinal use of cannabis based products and cannabinoidsTom P Freeman, Chandni Hindocha, Sebastian F Green, et al.
Social Cognitive and Affective Neuroscience|February 15, 2014
Dopamine, urges to smoke, and the relative salience of drug versus non-drug rewardTom P Freeman, Ravi K Das, Sunjeev K Kamboj, et al.
Addiction (Abingdon, England)|June 1, 2026
Can Thailand replace a commercialised cannabis market for adult use with a medical prescription model?Rasmon Kalayasiri, Woraphat Ratta-Apha, Jack Wilson, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 2, 2010
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]Celia J A Morgan, Gráinne Schafer, Tom P Freeman, et al.
The Lancet Regional Health. Europe|November 22, 2021
Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment ratesJakob Manthey, Tom P Freeman, Carolin Kilian, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 30, 2010
Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabisCelia J A Morgan, Tom P Freeman, Gráinne L Schafer, et al.
Addiction (Abingdon, England)|July 15, 2021
Weeding out the truth: a systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependenceJack Wilson, Katherine Mills, Tom P Freeman, et al.
The Lancet. Psychiatry|July 28, 2022
Association of cannabis potency with mental ill health and addiction: a systematic reviewKat Petrilli, Shelan Ofori, Lindsey Hines, et al.
Elife|November 13, 2019
The effects of psychosocial stress on dopaminergic function and the acute stress responseMichael Ap Bloomfield, Robert A McCutcheon, Matthew Kempton, et al.
The International Journal on Drug Policy|February 12, 2022
Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendeesMeryem Grabski, Jon Waldron, Tom P Freeman, et al.
Pageof 20